The dental bone graft substitute market is projected to expand from US$ 533.5 million in 2022 to US$ 1,011.2 million by 2030, reflecting a compound annual growth rate (CAGR) of 8.3% during this period.

Dental bone grafting is essential when there is a loss of bone in the jaw, often performed prior to the placement of dental implants or when bone loss adversely impacts adjacent teeth. This procedure enhances the volume and density of the jawbone in areas where it has diminished. The graft material can be sourced from the patient?s own body (autogenous), obtained from a human tissue bank (allograft), or derived from animal tissue (xenograft). In certain cases, synthetic materials (alloplasts) are utilized. The rapid growth of the dental bone graft substitute market is driven by the rising incidence of dental diseases and an increase in dental procedures motivated by cosmetic considerations. The escalating prevalence of dental issues, coupled with supportive government initiatives regarding dental bone graft substitutes, are significant factors propelling market growth.

Technological advancements are creating new opportunities for the dental bone graft substitute market. Innovations in technology enable dentists to perform procedures more efficiently, safely, and comfortably. Modern instruments have transformed dental hygiene appointments into more pleasant experiences for patients, leading to higher compliance and a willingness to schedule follow-up treatments. Restorative dentistry plays a crucial role in enhancing oral health, particularly in terms of facial aesthetics, functional teeth, and overall oral care. New dental implantation techniques, along with advanced navigation and monitoring technologies, allow for minimally invasive surgeries. Furthermore, augmented reality (AR) is increasingly utilized in reconstructive and aesthetic dental procedures, providing patients with a realistic digital preview of their post-treatment appearance. The growing acceptance of synthetic bone substitutes is also expected to boost the US dental bone graft substitute market. For instance, in 2020, Orthopediatrics Corp. launched QuickPack, an all-synthetic replacement featuring a high-viscosity calcium phosphate cement that mimics the mineral composition of natural bone. Similarly, Spine Wave Inc. introduced the tempest allograft bone matrix, which consists of cancellous and partially demineralized cortical bone. Such technological innovations are anticipated to foster growth in the dental bone graft substitute market in the years ahead.

Oral diseases, while largely preventable, remain a significant health concern in numerous countries, affecting individuals throughout their lives. Common dental issues include periodontal diseases, dental caries (tooth decay), and tooth loss. The rising prevalence of these conditions is driving the demand for dental replacements, crowns, copings, and bridges. According to the World Health Organization (WHO) Global Oral Health Status Report (2022), approximately 75% of the global population is affected by oral diseases, with around 3.5 billion individuals residing in middle-income countries. Additionally, about 2 billion people worldwide suffer from dental caries in their permanent teeth, and approximately 514 million children are affected by caries in their primary teeth. The increasing rates of dental problems, such as misaligned teeth, overbites, gaps, and overcrowding, are contributing to the demand for dental bone graft substitutes to address these issues. For example, the Centers for Disease Control and Prevention (CDC) reports that nearly 47.2% of adults over 30 in the US have some form of periodontal disease, a figure that rises with age; about 70.1% of adults aged 65 and older were affected by periodontal disease in 2020. This growing prevalence of dental diseases is driving the demand for dental bone graft substitutes, facilitating quicker and more effective treatments. Thus, the worldwide increase in oral health issues is significantly contributing to the expansion of the dental bone graft substitute market.

Geographically, the dental bone graft substitute market is divided into several regions: North America (including the US, Canada, and Mexico), Europe (comprising the UK, Germany, France, Italy, Spain, Russia, and the rest of Europe), Asia Pacific (including China, Japan, India, South Korea, Australia, Southeast Asia, and the rest of Asia Pacific), the Middle East & Africa (covering the UAE, Saudi Arabia, South Africa, and the rest of the region), and South & Central America (including Brazil, Argentina, and the rest of the region). In 2022, North America held the largest share of the global dental bone graft substitute market, driven by technological advancements, a rising incidence of dental diseases, an aging population, and a significant presence of key market players engaged in product development. However, the Asia Pacific region is expected to exhibit the highest CAGR from 2022 to 2030. The US accounted for the largest share of the North American market in 2022, with local companies employing both organic and inorganic strategies for market development. For instance, in September 2021, Straumann Group formed a strategic alliance with Aspen Dental Management, Inc. (ADMI) to provide dental implant solutions and CAD/CAM options to over 1,000 ADMI-affiliated practices across 45 states. Additionally, in January 2021, Nobel Biocare invited dental professionals to embrace the Mucointegration era by introducing the Xeal and TiUltra surfaces in the US, designed to enhance tissue integration at all levels. These factors collectively support the growth of the market. The significant rise in oral health issues, strategic initiatives by market players, and heightened awareness regarding dental consumables are indicative of the substantial market share and growth potential of dental consumables in Canada. A study by Smile Montreal Dentistry in 2020 revealed that approximately 98% of Canadians experience some form of oral condition in their lifetime, while research from the Canadian Dental Association indicates that about 70% of Canadians suffer from gum disease. Consequently, the increasing prevalence of dental issues in North America is driving the growth of the dental bone graft substitute market.

Key sources referenced in the preparation of this report include ClinicalTrails.com, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Health Services (NHS).